Abstract: Administration of ubidecarenone is effective for the therapy of sleep apnea. It is given at a dose of 1-3,000 mg per day in adults. It is especially effective to administer ubidecarenone to the patient before bed at a dose of 2-50 mg.

Abstract: A lipolytic enzyme inhibitor is disclosed which comprises as an active ingredient at least one of a basic protein, a basic polypeptide and salt thereof. The inhibitor is useful as a dieting agent for the prevention of obesity and lipemia and as an additive for food and feed.

Abstract: Disclosed are indole derivatives of formula (I) ##STR1## wherein X and Y each independently represent H or --CH.sub.2 CH.sub.2 R; R represents pyridyl or substituted amino of NR.sub.1 R.sub.2 ;R.sub.1 represents H or C.sub.1 -C.sub.6 alkyl;R.sub.2 represents 2-(3-indolyl)ethyl or aralkyl; orR.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached may form an N-containing 5 to 6 membered hetero ring, an N, O-containing hetero ring, which hetero ring may be fused with benzene;n is an integer of 4 to 8;with the proviso that X and Y both do not represent H or piperizinoethyl when n is 4, or pharmaceuticaly acceptable acid addition salts thereof. They are useful as an antiulcer agent.

Abstract: A method of inhibiting enzymatic hydrolysis of lipids in a mammal concerns orally administering an effective amount of a purothionin or an .epsilon.-polylysine of the formula: ##STR1## or a salt thereof, wherein n is a number of from 5 to 9, to a mammal in need thereof. Alternatively, the method concerns orally administering an .epsilon.-polylysine of the formula above or a salt thereof, wherein n is a number of from 4 to 30, to a mammal suffering from lipemia or obesity. The purothionin, .epsilon.-polylysine or salt thereof is a lipolytic enzyme inhibitor, useful as a dieting agent, an agent for the prevention of obesity and lipemia, and as an additive for food and feed.

Abstract: Diazabicyclo derivatives of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, oxoalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, acyl, dialkylaminoalkyl, hydroxyalkyl, haloalkyl, cyanoalkyl, heterocycloalkyl, aryl, heteroarylalkyl or arylalkyl, the aryl group and the aryl moiety being optionally substituted by alkoxy, nitro, alkyl, amino or halo;R.sup.2 is hydrogen or alkyl;R.sup.3 and R.sup.4 may be the same or different and each is hydrogen, alkyl, alkenyl, acyl, alkoxyalkyl or arylalkyl wherein the aryl moiety is optionally substituted by alkoxy, nitro, alkyl, amino or halo;with the proviso that when R.sup.2 is hydrogen and both R.sup.3 and R.sup.4 are methyl, R.sup.1 does not represent hydrogen, alkyl, unsubstituted benzyl or dimethylaminoethyl; having 5-HT.sub.3 receptor antagonist activity.

Abstract: Disclosed are opioid peptides recovered from hydrolysates of wheat proteins with an acid protease and further a neutral or alkaline protease. Of those peptides, the structure of four opioid peptides was identified by the amino acid sequence of Gly-Tyr-Tyr-Pro (SEQ ID NO: 1), Gly-Tyr-Tyr-Pro-Thr (SEQ ID NO: 2), Gly-Tyr-Tyr-Pro-Thr-Ser (SEQ ID NO: 3) or Tyr-Pro-Ile-Ser-Leu (SEQ ID NO: 4). They are useful as a medicine such as narcotic, analgesic or the like.

Abstract: A process for the preparation of an amylase inhibitor is disclosed which comprises the steps of:(a) extracting wheat, wheat flour or wheat gluten with water, a dilute acid, a dilute alkali or an aqueous alcohol to produce a solution containing the amylase inhibitor;(b) adding a polysaccharide to said solution to form an insoluble complex of the amylase inhibitor with the polysaccharide and separating the insoluble complex from the solution;(c) dissolving or dispersing said complex in a solution, then separating the polysaccharide from the solution to collect a solution containing the amylase inhibitor; and(d) treating the collected solution with a cation exchanger to recover the amylase inhibitor from fractions that have not been adsorbed on the cation exchanger.

Abstract: A powder supplying apparatus supplies, for example, a powder spraying apparatus with fine powder particles such as of ceramics having particle sizes of several .mu.m to 10 .mu.m at an extremely small rate of several grams to several tens of grams per hour, in the form of micronized discrete particles dispersed at a high degree of uniformity. The powder spraying apparatus is capable of spraying the fine powder particles on an object surface with a high degree of uniformity of distribution. The disclosed apparatus is used typically in uniformly spraying the above-mentioned fine powder particles which serve as spacers between a pair of transparent substrates of a liquid crystal display panel, for the purpose of maintaining a uniform and constant gap to be filled with a liquid crystal between these transparent substrates.

Abstract: Disclosed are indole derivatives of formula (I) ##STR1## wherein X and Y each independently represent H or --CH.sub.2 CH.sub.2 R;R represents pyridyl or substituted amino of NR.sub.1 R.sub.2 ;R.sub.1 represents H or C.sub.1 -C.sub.6 alkyl;R.sub.2 represents 2-(3-indolyl)ethyl or aralkyl; orR.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached may form an N-containing 5 to 6 membered hetero ring, an N, O-containing hetero ring, which hetero ring may be fused with benzene;n is an integer of 4 to 8;with the proviso that X and Y both do not represent H or piperizinoethyl when n is 4, or pharmaceuticaly acceptable acid addition salts thereof. They are useful as an antiulcer agent.

Abstract: Disclosed are (S)-2,3-dihydropolyprenol of formula (I) ##STR1## wherein m is 7 or 8 and (S)-2,3-dihydropolyprenyl monophosphate of formula (II) ##STR2## wherein m is 7 or 8 as well as pharmaceutically acceptable salts thereof. They are useful as a medicament for inhibiting the growth and/or metastasis of cancers.

Abstract: New compound, designated as leucanicidin, is now provided and is useful as insecticide. Leucanicidin is fermentatively produced by a microorganism Streptomyces halstedii No. 3002-14, (FEKM BP-493).

Abstract: Disclosed are opioid peptides recovered from hydrolysates of wheat proteins with an acid protease and further a neutral or alkaline protease. Of those peptides, the structure of four opioid peptides was identified by the amino acid sequence of Gly-Tyr-Tyr-Pro (SEQ ID NO:1), Gly-Tyr-Tyr-Pro-Thr (SEQ ID NO:2), Gly-Tyr-Tyr-Pro-Thr-Ser (SEQ ID NO:3) or Tyr-Pro-Ile-Ser-Leu (SEQ ID NO:4). They are useful as a medicine such as narcotic, analgesic or the like.

Abstract: A breadmaking dough conditioner is disclosed which comprises (a) an ascorbic acid, (b) at least one amino acid or salts thereof selected from the group consisting of cystine, methionine, asparagic acid, alanine, glycine and salts thereof, (c) an alum and (d) at least one emulsifier selected from the group consisting of a glycerol fatty acid monoester and a sucrose fatty acid ester having an HLB value of 5 to 10. The dough conditioners are especially suitable for the manufacture of bread using a frozen or chilled bread dough. They can prepare breads which have no fisheyes on the surface of the baked bread, have large bread volume and are good in all respects of appearance, inner phase, taste and flavor.

Abstract: Azabicyclo derivatives of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein A is a group of formula (a), (b) or (c): ##STR2## wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.10 alkyl, aralkyl or di(C.sub.1 -C.sub.4) alkylamino(C.sub.1 -C.sub.6)alkyl;R.sub.2, R.sub.3 and R.sub.4 may be the same or different and each is hydrogen, amino, halogen, C.sub.1 -C.sub.4 alkoxy or phthalimide;X is O or NH;R is C.sub.1 -C.sub.4 alkyl; andY is NR, O or S;having 5-HT.sub.3 receptor antagonist activity.

Abstract: The use of isoquinoline derivatives for the treatment of glaucoma or ocular hypertension. The isoquinoline derivatives are of formula I ##STR1## wherein R.sub.1 is a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group and R.sub.2 is a C.sub.1 -C.sub.6 alkyl group. The stability of the isoquinoline derivatives when used in the form of a solution is improved by incorporating therein compounds having a phenolic hydroxyl group and/or glycols serving as a stabilizer.

Abstract: Disclosed are indole derivatives of formula (I) ##STR1## wherein Y represents H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy or halogen;Z represents --CH.sub.2 N(R.sub.5)--;R represents H or --CH.sub.2 CH.sub.2 X where X represents pyridyl, aralkyloxy or substituted amino of NR.sub.6 R.sub.7 where R.sub.6 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl, C.sub.1 -C.sub.6 alkoxycarbonyl, aralkyloxycarbonyl or halogenated C.sub.1 -C.sub.6 alkoxycarbonyl and R.sub.7 represents H, C.sub.1 -C.sub.6 alkyl or aralkyl, or together with R.sub.2 may form a ring of --(CH.sub.2).sub.n -- (n is 1-4) or ##STR2## R.sub.1 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl or arylsulfonyl; R.sub.2 represents C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy or aralkyloxy;R.sub.3 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl or halogenated C.sub.1 -C.sub.6 alkyl;R.sub.4 and R.sub.5 may be the same or different and each represents H, C.sub.1 -C.sub.6 alkyl or aralkyl or both may together form a ring of --(CH.sub.2).sub.

Abstract: Compounds are disclosed of the formula ##STR1## wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.3 alkyl or diphenylmethyl; Y is --NH(CH.sub.2).sub.n --R.sub.2 ; R.sub.2 is OH or --ONO.sub.2 ; m is 2 or 3; and n is 9 to 13 or physiologically acceptable acid addition salts thereof. The compounds of formula (I) are of a blood flow-increasing and hypotensive actions and can be used for the therapy or prevention of diseases in the cardiovascular system.

Abstract: Disclosed are compounds of formula (I) ##STR1## in which A is ##STR2## The compounds are selective antagonists of 5HT at 5-HT.sub.3 receptors and useful in the treatment of psychotic disorders, neurotic diseases, gastric stasis symptoms, gastrointestinal disorders, nausea and vomiting.

Abstract: A method of coating powder particles includes the steps of circulating an air flow containing the powder particles in a dispersed state therein in a cylinder whose inner wall is wetted with a coating liquid to bring the powder particles into contact with the coating liquid on the inner wall, and drying the powder particles thus coated with the coating liquid. An apparatus for coating powder particles comprises a drying chamber including an inner space for drying powder particles on the surfaces of which a coating liquid is deposited while floating the powder particles by an air flow, a powder-particle feeding device connected to the top of the drying chamber for feeding an air flow containing dispersed powder particles into the inner space through a cylindrical path, and a coating-liquid supplying mechanism for wetting the inner wall of the cylindrical path of the powder-particle feeding means.

Abstract: The use of 1-phenoxycarbonyl-2-pyrrolidinone derivatives as an anti-platelet aggregating agent. The derivatives are of the formula ##STR1## wherein R is a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkoxy group, a nitro group or a halogen atom and n is 0, 1 or 2.